Proton vs Photon Therapy: HRQOL in Breast Cancer
here’s a breakdown of the key details from the provided text,focusing on the RadComp Consortium trial and its findings:
Key Findings:
* Comparable HRQOL: The RadComp Consortium trial (NCT02603341) demonstrated that health-related quality of life (HRQOL) was positive and similar between patients with non-metastatic breast cancer receiving proton therapy versus photon radiation therapy.
* No Clinically meaningful Differences: No meaningful differences were found in scores for PROMIS Fatigue, Satisfaction with Breast cosmetics Outcomes, BREAST-Q total score, or FACT-B trial outcome index between the two therapy groups.
* Shortness of Breath – Initial Finding, Later Questioned: Initially, the PRO-CTCAE assessment showed a trend towards fewer reports of shortness of breath with photon therapy (OR, 0.74; 95% CI, 0.59-0.93). However, after a “multiplicity analysis” (to account for multiple comparisons), this difference was no longer statistically significant.
* need for Further Research: While the shortness of breath finding lost significance, researchers acknowledge that multiplicity analyses can also increase the risk of missing true effects (false negatives). Therefore, further research is warranted.
Context & Presentation:
* presented at: The findings were presented at the 2025 american Society for Radiation Oncology Annual Meeting.
* Lead Researcher: Shannon MacDonald, MD, FASTRO, medical director at Southwest Florida Protons, presented the findings.
* Pneumonitis: Patients with breast cancer frequently enough experiance pneumonitis (lung inflammation) after radiation therapy, typically within 0-6 months.
In essence, the study suggests that proton and photon therapy have comparable effects on quality of life for patients with non-metastatic breast cancer, with a possibly minor initial finding regarding shortness of breath that requires further investigation.